The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 7, 2001, Pages 288-292

  Jazwinska Tarnawska, E ^a   Orzechowska Juzwenko, K ^a   Niewinski, P ^a   Rzemislawska, Z ^a   Loboz Grudzien K Dmochowska Perz, M ^a   Slawin, J ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Atrial fibrillation (AF); Oxidation phenotype; Propafenone (PPF)

Indexed keywords

ANTIARRHYTHMIC AGENT; CYTOCHROME P450 2D6; PROPAFENONE; SPARTEINE;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG OXIDATION; ENZYME POLYMORPHISM; FEMALE; GENE CONTROL; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; MALE; PHENOTYPE; PROPHYLAXIS; SINUS RHYTHM; STATISTICAL ANALYSIS;

EID: 0034952901     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39288     Document Type: Article

References (10)

1. Metabolic oxidation phenotype as markers for susceptibility to lung cancer
2. The genetic polymorphism of debrisoquine/sparteine metabolism - Clinical aspects
3. Genetic polymorphism in drug metabolism and its role in patient medication
4. Defective N-oxidation of sparteine in man; a new pharmacogenetic defect
5. Genetically determined interaction between propafenone and low-dose quinidine: Role of active metabolites in modulating net drug effect
6. High performance liquid chromatographic method for the simultaneous determination of propafenone and 5-hydroxypropafenone in human serum
7. Genetically determined sparteine oxidation polymorphism in a Polish population
8. Rola farmakogenetyki we wspólczesnej farmakoterapii
9. Polymorphism of propafenone metabolism and disposition in man: Clinical and pharmacokinetic consequences
10. Steady state plasma kinetics of slow-release propafenone, its two isomers and its metabolites